AHA: MedCo's PCSK9 rival inclisiran hits LDL

The Medicines Company has posted more late-phase data (PDF) linking its siRNA inclisiran to steep declines in LDL cholesterol. Inclisiran achieved a placebo-adjusted drop in LDL cholesterol of 58%, although it failed to drive the positive changes in cardiovascular outcomes seen in an earlier study.